UPDATE: Phase 1 Trial for RAD 402 Dosed the First Patient
Following our previous article, we are pleased to report that patient dosing has commenced in this trial. First patient has been dosed in this Phase 1 dose-escalation trial evaluating RAD 402, an anti-KLK3 (PSA) monoclonal antibody radiolabeled with Terbium-161 (Tb-161), in patients with advanced prostate cancer previously treated with standard therapies. Following our past article, […]
